Shanghai Henlius Biotech (HKG:2696) will set up two joint ventures with Saudi Arabia-based Al Tiryaq Al-Khalawi Medical or SVAX to produce and distribute pharmaceuticals in the Middle East, according to a Thursday press release by Henlius.
The Saudi Arabian company, owned by the Fakeeh family, together with Henlius, will market adalimumab and bevacizumab products, in the Middle East, North Africa, and Türkiye, according to the Hong Kong-listed company.
Adalimumab is indicated for rheumatoid arthritis and inflamed joints, while bevacizumab is a cancer treatment.
The two companies will also jointly develop pembrolizumab, another antibody for melanoma, lung cancer, Hodgkin lymphoma, and cancers of the stomach, cervix, head and neck
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。